MedTrace Logo

Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients

NCT06657755 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2024-10-24

No results posted yet for this study

Summary

This study aims to investigate the role of ENPP1 in bladder cancer (BC), specifically focusing on its impact on immune evasion, chemoresistance, and prognosis. The study will analyze gene expression data from clinical samples and use various laboratory techniques, including RNA sequencing, qRT-PCR, and immunohistochemistry, to assess ENPP1's expression levels. In addition, the research will explore the relationship between ENPP1 and immune cell infiltration, along with its correlation with patient survival outcomes. By identifying ENPP1's contribution to cancer progression and treatment resistance, the study aims to discover potential therapeutic targets for improving bladder cancer treatment strategies.

Conditions

  • Bladder (Urothelial, Transitional Cell) Cancer

Interventions

DIAGNOSTIC_TEST

Immunohistochemistry

This intervention will specifically focus on evaluating the role of ENPP1 in bladder cancer patients, distinguishing it from other interventions by targeting immune evasion and chemoresistance pathways. The intervention will include a combination of targeted molecular therapies and immunotherapy, aimed at assessing the therapeutic potential of ENPP1 inhibition in improving treatment outcomes for bladder cancer patients. This differs from previous studies by integrating advanced biomarker analysis and personalized treatment approaches based on ENPP1 expression levels.

Sponsors & Collaborators

  • Lanzhou University Second Hospital

    lead OTHER

Principal Investigators

  • Zhilong Dong, MD · Lanzhou University Second Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-10-01
Completion
2024-10-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06657755 on ClinicalTrials.gov